Kymera Therapeutics Inc
$ 107.52
1.04%
07 Aug - close price
- Market Cap 8,844,335,000 USD
- Current Price $ 107.52
- High / Low $ 108.12 / 104.78
- Stock P/E N/A
- Book Value 18.23
- EPS -3.25
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.24 %
- 52 Week High 130.05
- 52 Week Low 37.57
About
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$131.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-04-30 | 2026-02-26 | 2025-11-04 | 2025-08-11 | 2025-05-09 | 2025-02-27 | 2024-10-31 | 2024-08-07 | 2024-05-02 | 2024-02-22 | 2023-11-02 |
| Reported EPS | -0.62 | -0.71 | -0.97 | -0.94 | -0.95 | -0.82 | -0.89 | -0.82 | -0.58 | -0.62 | -0.25 | -0.9 |
| Estimated EPS | -0.64 | -0.86 | -0.77 | -0.78 | -0.8 | -0.91 | -0.7882 | -0.84 | -0.66 | -0.72 | -0.4 | -0.7 |
| Surprise | 0.02 | 0.15 | -0.2 | -0.16 | -0.15 | 0.09 | -0.1018 | 0.02 | 0.08 | 0.1 | 0.15 | -0.2 |
| Surprise Percentage | 3.125% | 17.4419% | -25.974% | -20.5128% | -18.75% | 9.8901% | -12.9155% | 2.381% | 12.1212% | 13.8889% | 37.5% | -28.5714% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KYMR
2026-08-08 08:10:11
The California State Teachers Retirement System increased its stake in Kymera Therapeutics (NASDAQ:KYMR) by 23% in the first quarter, owning 56,282 shares valued at $4.7 million. Despite recent insider selling, analyst sentiment for Kymera Therapeutics remains positive, with a "Moderate Buy" consensus rating and an average price target of $125.65. The company recently exceeded quarterly expectations, reporting an adjusted loss of $0.62 per share and a significant revenue increase of 465.2% year-over-year.
2026-08-07 10:09:40
Brookline Capital Markets has reduced its Q3 2026 EPS forecast for Kymera Therapeutics to a loss of $1.31 per share, though it maintained a "Buy" rating. Despite the lowered forecast, Kymera reported a strong Q2, beating revenue and EPS expectations due to milestone payments and increased revenue. The company anticipates its cash runway will extend into 2029 and has several clinical catalysts expected by year-end 2026, though insider selling remains a notable activity.
2026-08-06 18:10:36
Kymera Therapeutics, Inc. (KYMR) has seen its average 12-month price target increased by analysts from $127.18 to $128.91, implying a potential 23% upside from its August 4th closing price. The consensus rating among 24 covering analysts remains "Buy," with 21 recommending Buy and 3 Hold.
2026-08-06 18:09:40
Kymera Therapeutics reported its Q2 2026 financial results, posting a narrower-than-expected loss of $0.62 per share, surpassing the consensus estimate. The company's revenue surged to $65.0M, reflecting strong growth driven by its protein degradation platform. This performance indicates substantial year-over-year improvement and accelerating momentum for its clinical-stage pipeline.
2026-08-06 11:16:52
Kymera Therapeutics (KYMR) saw its stock rise slightly after its Q2 earnings, reporting $65 million in collaboration revenue but ongoing net losses of over $60 million. The market views this as a steady update rather than a breakthrough, with investors questioning the durability of revenue heavily reliant on one-time partnership milestones against persistent high spending and losses. While the company highlights progress in its clinical pipeline and a cash runway into 2029, critics point to the dependency on collaboration revenue and substantial cash burn as significant concerns.
2026-08-06 10:13:00
Citigroup has increased its target price for KYMERA THERAPEUTICS, INC. (KYMR.O) to $135, up from the previous target of $120. This adjustment reflects Citigroup's updated outlook for the pharmaceutical company. The article, disseminated by Reuters, serves as a financial news update for investors.
